Bayer Pharmaceuticals located in Loos is one of the three divisions of Bayer Group in France. The pharmaceutical activities of Bayer include: General Medicine (cardiology, women’s health), Specialized Medicine (hemophilia, oncology), Ophthalmology and Radiology. Bayer Pharmaceuticals is one of the top ten pharmaceutical laboratories in the world.
Bayer’s products help to address the increasing challenges of a growing and aging population and the resulting demand for innovative medicines. With innovative products, Bayer seeks to achieve therapeutic benefit for patients, while at the same time satisfying the growing requirements of physicians and health insurers.
Bayer devotes a large part of its sales (17.5%) to Research and Development in Pharmaceuticals, especially in the following therapeutic areas: oncology, cardiology, gynecology and ophthalmology.
Bayer is a research-driven company which growth is based in its established business areas through investment in research and development as well as through acquisitions and collaborations with external partners in academia and industry.
General Director Bayer HealthCare SAS & Head of Pharmaceuticals
ONTEX is an international leader in the manufacture of personal hygiene solutions for babies, women and adults.
“The decision to set up our new factory in Wasquehal was an easy choice given the numerous accessibility benefits, both in terms of logistics and being closer to our clients in France, Belgium and the United Kingdom. Thanks to the Regional Council, our installation works progressed quickly and within our deadlines. One of the main keys to our development lies in our staff, who have a vital knowhow and are a valuable resource”
Xavier Lambrecht, General Manager Healthcare Division Ontex
In 2014 AMPHASTAR acquired the Dutch company DIOSYNTH, which was established in the Netherlands in 1930 and which is based in the Oise region in France. The company specialises in the development of insulin derivatives.
“The unique knowhow that exists in the Oise region is complemented by an excellent network of superior higher education institutions. There is also a culture of science due to, in particular, the Technical University of Compiègne (UTC), which fosters the development of highly-qualified staff. In addition to this, the location is ideal, at the heart of Europe and close to the Paris Charles de Gaulle airport. This makes it easy for our US-based parent company to reach us. There are also numerous fiscal benefits for companies in France. For example, the strategic investment of establishing our manufacturing facility in France makes us eligible for the tax credit for industrial investment, which will ultimately enable us to employ 40 new staff members”
Franck VITALI, Senior Plant Manager